Evaluation of prostate cancer antigen 3 for detecting prostate cancer: A systematic review and meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cui, Yong ^a   Cao, Wenzhou ^a   Li, Quan ^a   Shen, Hua ^a   Liu, Chao ^a   Deng, Junpeng ^a   Xu, Jiangfeng ^b   Shao, Qiang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

HUMAN; MALE; META ANALYSIS; METABOLISM; ODDS RATIO; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINE;

ANTIGENS, NEOPLASM; HUMANS; MALE; ODDS RATIO; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84968698081     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25776     Document Type: Article

References (63)

1. Shao Q., et al. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration. Cancer Lett 315, 170-177, doi: 10.1016/j.canlet.2011.09.035 (2012
2. Siegel R., Ma J., Zou Z., & Jemal A. Cancer statistics, 2014. CA Cancer J Clin 64, 9-29, doi: 10.3322/caac.21208 (2014
3. Bussemakers M. J., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59, 5975-5979 (1999
4. Liberati A., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700, doi: 10.1136/bmj.b2700 (2009
5. Whiting P., Rutjes A. W., Reitsma J. B., Bossuyt P. M., & Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3, 25, doi: 10.1186/1471-2288-3-25 (2003
6. Hessels D., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44, 8-15; discussion 15-16 (2003
7. Fradet Y., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64, 311-315; discussion 315-316, doi: 10.1016/j.urology.2004.03.052 (2004
8. Tinzl M., Marberger M., & Horvath S., & Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 46, 182-186; discussion 187, doi: 10.1016/j.eururo.2004.06.004 (2004
9. Groskopf J., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52, 1089-1095, doi: 10.1373/clinchem.2005.063289 (2006
10. van Gils M. P., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13, 939-943, doi: 10.1158/1078-0432.CCR-06-2679 (2007
11. van Gils M. P., et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67, 881-887, doi: 10.1002/pros.20564 (2007
12. Marks L. S., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69, 532-535, doi: 10.1016/j.urology.2006.12.014 (2007
13. Deras I. L., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179, 1587-1592, doi: 10.1016/j. juro.2007.11.038 (2008
14. Haese A., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54, 1081-1088, doi: 10.1016/j.eururo.2008.06.071 (2008
15. Laxman B., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68, 645-649, doi: 10.1158/0008-5472.CAN-07-3224 (2008
16. Ouyang B., et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 181, 2508-2513; discussion 2513-2504, doi: 10.1016/j.juro.2009.01.110 (2009
17. Shappell S. B., et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 73, 363-368, doi: 10.1016/j.urology.2008.08.459 (2009
18. Wang R., Chinnaiyan A. M., Dunn R. L., Wojno K. J., & Wei J. T. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 115, 3879-3886, doi: 10.1002/cncr.24447 (2009
19. Mearini E., et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers 14, 235-243, doi: 10.1080/13547500902807306 (2009
20. Henderson J., et al. The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate. J Endourol 24, 1821-1824, doi: 10.1089/end.2010.0196 (2010
21. Aubin S. M., et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184, 1947-1952, doi: 10.1016/j.juro.2010.06.098 (2010
22. Auprich M., et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58, 727-732, doi: 10.1016/j.eururo.2010.06.038 (2010
23. Morote J., et al. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol 28, 677-680, doi: 10.1007/s00345-010-0580-0 (2010
24. Nyberg M., et al. PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population. Scand J Urol Nephrol 44, 378-383, doi: 10.3109/00365599.2010.521187 (2010
25. Roobol M. J., et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58, 475-481, doi: 10.1016/j.eururo.2010.06.039 (2010
26. Rigau M., et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 70, 1760-1767, doi: 10.1002/pros.21211 (2010
27. Shen M., et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol 90, 97-100, doi: 10.1016/j.yexmp.2010.10.009 (2011
28. Schilling D., et al. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. Urol Int 85, 159-165, doi: 10.1159/000314078 (2010
29. Rubio-Briones J., et al. [Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]. Actas Urol Esp 35, 589-596, doi: 10.1016/j.acuro.2011.04.001 (2011
30. Adam A., et al. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. BJU Int 108, 1728-1733, doi: 10.1111/j.1464-410X.2011.10202.x (2011
31. Cao D. L., et al. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71, 700-710, doi: 10.1002/pros.21286 (2011
32. Ochiai A., et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol 18, 200-205, doi: 10.1111/j.1442-2042.2010.02711.x (2011
33. Perdona S., et al. Prostate cancer detection in the grey area of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun?s nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 59, 81-87, doi: 10.1016/j.eururo.2010.09.036 (2011
34. de la Taille A., et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 185, 2119-2125, doi: 10.1016/j. juro.2011.01.075 (2011
35. Barbera M., Pepe P., Paola Q., & Aragona F. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients. Arch Ital Urol Androl 84, 227-229 (2012
36. Ng C. F., et al. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J 18, 459-465 (2012
37. Crawford E. D., et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 188, 1726-1731, doi: 10.1016/j.juro.2012.07.023 (2012
38. Pepe P., & Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res 31, 4445-4449 (2011
39. Pepe P., Fraggetta F., Galia A., Skonieczny G., & Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?. Int Braz J Urol 38, 489-495 (2012
40. Sciarra A., et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int 110, 1661-1665, doi: 10.1111/j.1464-410X.2012.11146.x (2012
41. Wu A. K., Reese A. C., Cooperberg M. R., Sadetsky N., & Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis 15, 100-105, doi: 10.1038/pcan.2011.52 (2012
42. Ferro M., et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One 8, e67687, doi: 10.1371/journal.pone.0067687 (2013
43. Goode R. R., Marshall S. J., Duff M., Chevli E., & Chevli K. K. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 73, 48-53, doi: 10.1002/pros.22538 (2013
44. Ochiai A., et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 111, 928-933, doi: 10.1111/j.1464-410X.2012.11683.x (2013
45. Stephan C., et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2: ERG gene fusion with the serum [-2] proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 59, 280-288, doi: 10.1373/clinchem.2012.195560 (2013
46. Perdona S., et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73, 227-235, doi: 10.1002/pros.22561 (2013
47. Salagierski M., Mulders P., & Schalken J. A. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res 33, 553-557 (2013
48. Scattoni V., et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 190, 496-501, doi: 10.1016/j.juro.2013.02.3184 (2013
49. Chevli K. K., et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol 191, 1743-1748, doi: 10.1016/j.juro.2013.12.005 (2014
50. Porpiglia F., et al. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?. J Urol 192, 60-66, doi: 10.1016/j.juro.2014.01.030 (2014
51. Albino G., et al. Evaluation of the diagnostic and predictive power of PCA3 in the prostate cancer. A different best cut-off in each different scenario. Preliminary results. Arch Ital Urol Androl 86, 306-310, doi: 10.4081/aiua.2014.4.306 (2014
52. Hansen J., et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 63, 201-209, doi: 10.1016/j.eururo.2012.07.030 (2013
53. Heidenreich A., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59, 61-71, doi: 10.1016/j.eururo.2010.10.039 (2011
54. Mohler J. L. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 8, 145 (2010
55. Greene K. L., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 182, 2232-2241, doi: 10.1016/j. juro.2009.07.093 (2009
56. Schalken J. A., Hessels D., & Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3 (PCA3)), a highly prostate cancer-specific gene. Urology 62, 34-43 (2003
57. Salagierski M., et al. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate 70, 70-78, doi: 10.1002/pros.21040.(2010
58. Clarke R. A., et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PloS one 4, e4995, doi: 10.1371/journal.pone.0004995 (2009
59. Ferreira L. B., et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC cancer 12, 507, doi: 10.1186/1471-2407-12-507 (2012
60. Herness E. A., & Naz R. K. A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis. Cancer research 63, 329-336 (2003
61. Luo J., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62, 2220-2226 (2002
62. Korkmaz K. S., et al. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 277, 36689-36696, doi: 10.1074/jbc.M202414200 (2002
63. Wang W., et al. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. Sci Rep 4, 5012, doi: 10.1038/srep05012 (2014